journal
Journals Critical Reviews in Oncology/h...

Critical Reviews in Oncology/hematology

https://read.qxmd.com/read/39245299/metabolic-risk-factors-of-colorectal-cancer-umbrella-review
#1
REVIEW
Meseret Derbew Molla, Erin L Symonds, Jean M Winter, Ayal Debie, Molla M Wassie
BACKGROUND AND AIM: The association between metabolic factors and colorectal cancer (CRC) risk is inconclusive. This umbrella review aimed to summarise and describe the association using existing systematic reviews and/or meta-analyses. METHOD: Four databases (Medline, Scopus, Web of Science, and Cochrane Library) were searched for systematic reviews and/or meta-analyses of observational studies. Two independent authors extracted data on the summary estimated effect and heterogeneity of studies using I2 from the individual reviews...
September 6, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39245298/minimal-residual-disease-testing-for-classical-hodgkin-lymphoma-a-comprehensive-review
#2
REVIEW
Momo Arai, Alaa Hamad, Yazan Almasry, Abdullah Alamer, Walid Rasheed, Mahmoud Aljurf, Riad El Fakih
Classical Hodgkin lymphoma (cHL) is a common lymphoma that affects young patients. Fortunately, the disease is highly curable as it is susceptible to the currently available treatment modalities. Disease monitoring with Positron Emission Tomography and Computed Tomography (PET/ CT) is an integral part of managing these patients. PET guided protocols are currently used to adjust treatment according to the response. The pivotal idea behind the use of response-adapted approaches is to preserve efficacy while decreasing the toxicity...
September 6, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39245297/facing-the-climate-change-is-radiotherapy-as-green-as-we-would-like-a-systematic-review
#3
REVIEW
Stefania Volpe, Federico Mastroleo, Maria Giulia Vincini, Mattia Zaffaroni, Alice Porazzi, Ernesto Damiani, Giulia Marvaso, Barbara Alicja Jereczek-Fossa
PURPOSE: To focus on the ecological footprint of radiotherapy (RT), on opportunities for sustainable practices, on future research directions. METHODS: Different databases were interrogated using the following terms: Carbon Footprint, Sustainab*, Carbon Dioxide, Radiotherapy, and relative synonyms. RESULTS: 931 records were retrieved; 15 reports were included in the review. Eight main thematic areas have been identified. Nine research works analyzed the environmental impact of photon-based external beam RT...
September 6, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39245296/colorectal-cancer-with-braf-v600e-mutation-trends-in-immune-checkpoint-inhibitor-treatment
#4
REVIEW
Mengling Liu, Qing Liu, Keshu Hu, Yu Dong, Xun Sun, Zhiguo Zou, Dingkun Ji, Tianshu Liu, Yiyi Yu
Colorectal cancer (CRC) with BRAF V600E mutation presents a formidable scientific and clinical challenge due to its aggressive nature and poor response to standard therapeutic approaches. BRAF V600E mutation-induced conspicuous activation of the MAPK pathway contributes to the relentless tumor progression. Nevertheless, the efficacy of multi-targeted MAPK pathway inhibition remains suboptimal in clinical practice. Patients with high microsatellite instability (MSI-H) have shown favorable results with immune checkpoint inhibitors (ICIs)...
September 6, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39244180/management-of-peripheral-neuropathy-associated-with-brentuximab-vedotin-in-the-frontline-treatment-of-classical-hodgkin-lymphoma
#5
REVIEW
Jeremy S Abramson, Robert Stuver, Alex Herrera, Emily Patterson, Yi-Ping Wen, Alison Moskowitz
The ECHELON-1 trial demonstrated the effectiveness of brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine as a frontline treatment regimen in classical Hodgkin lymphoma. However, peripheral neuropathy (PN) is common with this regimen, occurring in up to two-thirds of patients. While standard prescribing information recommends BV dose modification at the onset of grade 2 PN, management strategies for PN are not well-defined. Most commonly, clinicians dose reduce or discontinue BV, vinblastine, or both...
September 5, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39244179/epigenetic-modifying-agents-the-potential-game-changers-in-the-treatment-of-hematologic-malignancies
#6
REVIEW
Tahereh Hojjatipour, Mina Ajeli, Amirhosein Maali, Mehdi Azad
Hematologic malignancies are lethal diseases arising from accumulated leukemic cells with substantial genetic or epigenetic defects in their natural development. Epigenetic modifications, including DNA methylation and histone modifications, are critical in hematologic malignancy formation, propagation, and treatment response. Both mutations and aberrant recruitment of epigenetic modifiers are reported in different hematologic malignancies, which regarding the reversible nature of epigenetic regulations, make them a potential target for cancer treatment...
September 5, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39236904/tigit-will-it-be-the-next-star-therapeutic-target-like-pd-1-in-hematological-malignancies
#7
REVIEW
Yang Liu, Wenhui Liu, Tao Wu
Research on the mechanism and application of checkpoint inhibitory receptors in hematologic diseases has progressed rapidly. However, in the treatment of relapserefractory (R/R) hematologic malignancies and anti-programmed cell death protein 1 (PD-1), patients who are resistant to anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) are in urgent need of alternative therapeutic targets. T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) has a broad prospect as an inhibitory receptor like PD-1, but its more specific mechanism of action and application in hematologic diseases still need to be further studied...
September 3, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39233128/the-emerging-role-of-artificial-intelligence-in-proton-therapy-a-review
#8
REVIEW
Lars Johannes Isaksson, Federico Mastroleo, Maria Giulia Vincini, Giulia Marvaso, Mattia Zaffaroni, Michal Gola, Giovanni Carlo Mazzola, Luca Bergamaschi, Simona Gaito, Filippo Alongi, Jerome Doyen, Piero Fossati, Karin Haustermans, Morten Høyer, Johannes Albertus Langendijk, Raùl Matute, Ester Orlandi, Marco Schwarz, Esther G C Troost, Vladimir Vondracek, Davide La Torre, Giuseppe Curigliano, Giuseppe Petralia, Roberto Orecchia, Daniela Alterio, Barbara Alicja Jereczek-Fossa
Artificial intelligence (AI) has made a tremendous impact in the space of healthcare, and proton therapy is not an exception. Proton therapy has witnessed growing popularity in oncology over recent decades, and researchers are increasingly looking to develop AI and machine learning tools to aid in various steps of the treatment planning and delivery processes. This review delves into the emergent role of AI in proton therapy, evaluating its development, advantages, intended clinical contexts, and areas of application...
September 2, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39197669/role-of-mitochondria-and-potential-of-mitochondria-targeted-therapy-in-braf-mutant-cancer-a-review
#9
REVIEW
Yanyan Gao, Hua Zheng
The classical mitogen-activated protein kinase (MAPK) signaling pathway, the Ras/Raf/MEK (mitogen-activated protein kinase/ERK kinase)/ERK protein kinase cascade, is a conserved cascade that regulates cell growth, differentiation, and proliferation. The significance of BRAF in cancer was established with the discovery of cancer-activating mutations in BRAF in several human tumors in 2002. Currently, BRAF is recognized as a driver mutation that affects cancer phenotypes in different ways, making it an important therapeutic target for cancer...
August 26, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39197668/definitive-radiotherapy-and-trismus-in-hnc-patients-a-critical-review
#10
REVIEW
Orges Spahiu, Cristiano Grossi, Chiara Cavallin, Valeria Chiofalo, Erica Maria Cuffini, Bruna Lo Zito, Francesca Catena, Alessandro Tortarolo, Mario Levis, Maria Grazia Piancino, Umberto Ricardi, Giuseppe Carlo Iorio
INTRODUCTION: Trismus is a potentially critical morbidity following curative-intended radiotherapy in head and neck cancer patients. However, in this setting, evidence regarding this side effect remains to be fully defined, particularly in terms of dosimetric parameters. MATERIALS AND METHODS: Key references were derived from a PubMed query. Hand searching and clinicaltrials.gov were also used. RESULTS: This paper contains a narrative report and a critical discussion of the evidence on radiation-induced trismus in the literature, particularly the dosimetric concerns...
August 26, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39159706/unveiling-the-impact-of-circulating-tumor-cells-two-decades-of-discovery-and-clinical-advancements-in-solid-tumors
#11
REVIEW
Carolina Reduzzi, Eleonora Nicolo', Surbhi Singhal, Konstantinos Venetis, Ana Ortega-Franco, Diego de Miguel-Perez, Angelo Dipasquale, Mohamed A Gouda, Erick Figueiredo Saldanha, Pashtoon M Kasi, Eloisa Jantus Lewintre, Nicola Fusco, Umberto Malapelle, David R Gandara, Christian Rolfo, Maria Jose Serrano, Massimo Cristofanilli
Circulating tumor cells (CTCs) enumeration and molecular profiling hold promise in revolutionizing the management of solid tumors. Their understanding has evolved significantly over the past two decades, encompassing pivotal biological discoveries and clinical studies across various malignancies. While for some tumor types, such as breast, prostate, and colorectal cancer, CTCs are ready to enter clinical practice, for others, additional research is required. CTCs serve as versatile biomarkers, offering insights into tumor biology, metastatic progression, and treatment response...
August 17, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39159705/unleashing-precision-a-review-of-targeted-approaches-in-pleural-mesothelioma
#12
REVIEW
Mario Occhipinti, Marta Brambilla, Raimondo Di Liello, Paolo Ambrosini, Lorenzo Lobianco, Rita Leporati, Maria Salvarezza, Fabiana Vitiello, Silvia Marchesi, Sara Manglaviti, Teresa Beninato, Laura Mazzeo, Claudia Proto, Arsela Prelaj, Roberto Ferrara, Carminia Maria Della Corte, Giuseppe Lo Russo, Filippo de Braud, Monica Ganzinelli, Giuseppe Viscardi
This review delves into the intricate landscape of pleural mesothelioma (PM), emphasizing the need for nuanced therapeutic strategies. While platinum-based chemotherapy remains a cornerstone, the advent of immune checkpoint inhibitors (ICIs), notably through the Checkmate 743 trial, has reshaped treatment paradigms. Challenges persist due to patient heterogeneity and a lack of specific biomarkers. Targeting genotypic and phenotypic alterations emerges as a promising avenue, demanding precision oncology in this rare disease...
August 17, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39154670/metabolic-interactions-of-host-gut-microbiota-new-possibilities-for-the-precise-diagnosis-and-therapeutic-discovery-of-gastrointestinal-cancer-in-the-future-a-review
#13
REVIEW
Jianing Yu, Lu Li, Xufeng Tao, Yanwei Chen, Deshi Dong
Gastrointestinal (GI) cancer continues to pose a significant global health challenge. Recent advances in our understanding of the complex relationship between the host and gut microbiota have shed light on the critical role of metabolic interactions in the pathogenesis and progression of GI cancer. In this study, we examined how microbiota interact with the host to influence signalling pathways that impact the formation of GI tumours. Additionally, we investigated the potential therapeutic approach of manipulating GI microbiota for use in clinical settings...
August 16, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39153703/a-neuroendocrine-biomarker-revolution-from-monoanalyte-to-multianalyte-biomarkers-in-non-functioning-gastro-entero-pancreatic-neuroendocrine-neoplasms
#14
REVIEW
Camilla O Hoff, Joao Manzi, Raphaella Ferreira, Aman Chauhan, Peter Housein, Nipun Merchant, Alan Livingstone, Rodrigo Vianna, Phillipe Abreu
Neuroendocrine neoplasms (NENs) arise from neuroendocrine cells in a wide variety of organs. One of the most affected disease sites is the gastrointestinal system, which originates the gastro-entero-pancreatic NENs (GEP-NENs), a heterogenous group of malignancies that are rapidly increasing in incidence. These tumors can be functioning, with secretory activity leading to identifiable clinical syndromes, or non-functioning, with no secretory activity but with local symptoms of tumor growth and metastasis. A limitation in biomarkers is a crucial unmet need in non-secretory NEN management, as clinical decision-making is made more difficult by obstacles in tumor classification, prognostic evaluation, assessment of treatment response and surveillance...
August 15, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39151838/clinical-applications-of-radiomics-and-deep-learning-in-breast-and-lung-cancer-a-narrative-literature-review-on-current-evidence-and-future-perspectives
#15
REVIEW
Alessandra Ferro, Michele Bottosso, Maria Vittoria Dieci, Elena Scagliori, Federica Miglietta, Vittoria Aldegheri, Laura Bonanno, Francesca Caumo, Valentina Guarneri, Gaia Griguolo, Giulia Pasello
Radiomics, analysing quantitative features from medical imaging, has rapidly become an emerging field in translational oncology. Radiomics has been investigated in several neoplastic malignancies as it might allow for a non-invasive tumour characterization and for the identification of predictive and prognostic biomarkers. Over the last few years, evidence has been accumulating regarding potential clinical applications of machine learning in many crucial moments of cancer patients' history. However, the incorporation of radiomics in clinical decision-making process is still limited by low data reproducibility and study variability...
August 14, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39151837/management-of-hodgkin-lymphoma-during-pregnancy-review-of-the-literature-and-description-of-an-homogenous-expectative-attitude-associated-with-excellent-outcome
#16
REVIEW
Joshua Hagège, Lorea Aguinaga, Hannah Moatti, Roberta Di Blasi, Catherine Thieblemont, Pauline Brice, Loïc Renaud
Hodgkin lymphoma (HL) occuring during pregnancy is a rare condition, and management relies on sparse literature. The specificity of pregnancy requires the clinician to take into account the clinical emergency, the stage of the lymphoma, the trimester of pregnancy, and the patient's choices. The main objective is twofold: to limit the risk of toxicity and adverse events for both mother and fetus, without reducing the chances of a successful outcome. Current literature data suggest that the use of ABVD-type polychemotherapy (adriamycin, bleomycin, vinblastine, dacarbazine) is associated with obstetrical events and long-term fetal toxicity...
August 14, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39127520/corrigendum-to-surrogate-endpoints-in-phase-iii-randomized-trials-of-advanced-gastroesophageal-cancer-a-systematic-review-and-meta-analysis-crit-rev-oncol-hematol-%C3%A2-201-2024-104416
#17
Joel Veas Rodríguez, Ana Prieto, Ester Vilaprinyo, Marta Bonet, Marc Diez, Antonieta Salud, Robert Montal
No abstract text is available yet for this article.
August 9, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39127134/the-burden-of-pediatric-critical-illness-among-pediatric-oncology-patients-in-low-and-middle-income-countries-a-systematic-review-and-meta-analysis
#18
REVIEW
Alejandra Gabela, Roelie M Wösten-van Asperen, Anita V Arias, Carlos Acuña, Zebin Al Zebin, Eliana Lopez-Baron, Parthasarathi Bhattacharyya, Lauren Duncanson, Daiane Ferreira, Sanjeeva Gunasekera, Samantha Hayes, Jennifer McArthur, Vaishnavi Divya Nagarajan, Maria Puerto Torres, Jocelyn Rivera, Elizabeth Sniderman, Jordan Wrigley, Huma Zafar, Asya Agulnik
BACKGROUND: Pediatric oncology patients have increased risk for critical illness; outcomes are well described in high-income countries (HICs); however, data is limited for low- and middle-income countries (LMICs). METHODS: We systematically searched PubMed, EMBASE, Web of Science, CINAHL and Global Health databases for articles in 6 languages describing mortality in children with cancer admitted to intensive care units (ICUs) in LMICs. Two investigators independently assessed eligibility, data quality, and extracted data...
August 8, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39097247/current-mrna-based-vaccine-strategies-for-glioma-treatment
#19
REVIEW
Mengqian Mao, Wanchun Yang, Xuefeng Zhang
Gliomas are one of the most aggressive types of brain tumors and are associated with high morbidity and mortality rates. Currently, conventional treatments for gliomas such as surgical resection, radiotherapy, and chemotherapy have limited effectiveness, and new approaches are needed to improve patient outcomes. mRNA-based vaccines represent a promising therapeutic strategy for cancer treatment, including gliomas. Recent advances in immunotherapy using mRNA-based dendritic cell vaccines have shown great potential in preclinical and clinical trials...
August 7, 2024: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/39117163/advancements-in-tumor-infiltrating-lymphocytes-historical-insights-contemporary-milestones-and-future-directions-in-oncology-therapy
#20
REVIEW
Muhammad Aizaz, Alina Sami Khan, Maria Khan, Elshan Musazade, Guiwen Yang
Tumor-infiltrating lymphocytes (TILs) are a subtype of immune cells that infiltrate and accumulate within tumors. Studies proved that TILs can be used as prognostic and predictive markers for cancer patients' responses to immunotherapy. This review explores the modern knowledge of TILs, the challenges and opportunities for utilizing TILs in cancer treatment, such as the rise of therapies under TIL circumstances, the identification of biomarkers for TIL activity, and methods used to isolate and expand TILs for therapeutic use...
August 6, 2024: Critical Reviews in Oncology/hematology
journal
journal
20089
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.